AstraZeneca, Sanofi RSV infant shots approved in China
Send a link to a friend
[January 02, 2024]
(Reuters) -AstraZeneca said on Tuesday that its respiratory
syncytial virus (RSV) immunization for infants developed with Sanofi has
got approval in China.
The drug makers co-developed the RSV shot for infants and toddlers
called Beyfortus, which has already been approved for use in the
European Union and United States.
Beyfortus is expected to be available in China during the upcoming
2024-2025 RSV season, the London-listed drug maker said in a statement.
RSV, a highly contagious seasonal virus known for cold-like symptoms, is
a leading cause of hospitalization in both infants and the elderly.
Regulatory applications for the drug are currently under review in Japan
and several other countries, the company added.
[to top of second column]
|
![](../images/010224PIX/health64.jpg)
The logo for AstraZeneca is seen outside its North America
headquarters in Wilmington, Delaware, U.S., March 22, 2021.
REUTERS/Rachel Wisniewski
![](http://archives.lincolndailynews.com/2024/Jan/02/images/ads/current/peasleymemorials_lda_2022.png) (Reporting by Eva Mathews in
Bengaluru; Editing by Dhanya Ann Thoppil)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |